These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34867403)

  • 1. Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch.
    Wang X; Gou X; Yu X; Bai D; Tan B; Cao P; Qian M; Zheng X; Wang H; Tang P; Zhang C; Ye F; Ni J
    Front Pharmacol; 2021; 12():773204. PubMed ID: 34867403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZYKR1, a novel, potent, and peripherally selective kappa opioid receptor agonist reduces visceral pain and pruritus in animal models.
    Jain MR; Patel RB; Prajapati KD; Vyas P; Bandyopadhyay D; Prajapati V; Bahekar R; Patel PN; Kawade HM; Kokare DM; Pawar V; Desai R
    Eur J Pharmacol; 2022 Jun; 924():174961. PubMed ID: 35443192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conorphin-66 produces peripherally restricted antinociception via the kappa-opioid receptor with limited side effects.
    Xu K; Zhang M; Chen D; Xu B; Hu X; Zhang Q; Zhang R; Zhang N; Li N; Fang Q
    Neuropharmacology; 2024 Dec; 261():110157. PubMed ID: 39276862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Intrathecal κ-Opioid Receptor Agonist on Morphine-Induced Itch and Antinociception in Mice.
    Sakakihara M; Imamachi N; Saito Y
    Reg Anesth Pain Med; 2016; 41(1):69-74. PubMed ID: 26587674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria.
    Brust TF; Morgenweck J; Kim SA; Rose JH; Locke JL; Schmid CL; Zhou L; Stahl EL; Cameron MD; Scarry SM; Aubé J; Jones SR; Martin TJ; Bohn LM
    Sci Signal; 2016 Nov; 9(456):ra117. PubMed ID: 27899527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of butorphanol on morphine-induced itch and analgesia in primates.
    Lee H; Naughton NN; Woods JH; Ko MC
    Anesthesiology; 2007 Sep; 107(3):478-85. PubMed ID: 17721251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of HSK21542 for hemodialysis patients: a multiple ascending dose study.
    Pan M; Wang G; Zhou L; Xu Y; Yao L; Wu C; Mei C; Zhao Z; Sun D; Guan T; Chen Q; Shi M; Xu H; Zeng W; Li F; Yan R; Liu BC
    Front Pharmacol; 2023; 14():1203642. PubMed ID: 37876731
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Huang P; Ho CK; Cao D; Inan S; Rawls SM; Li M; Huang B; Pagare PP; Townsend EA; Poklis JL; Halquist MS; Banks M; Zhang Y; Liu-Chen LY
    J Pharmacol Exp Ther; 2024 Feb; 389(1):106-17. PubMed ID: 38409113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.
    Morgenweck J; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
    Neuropharmacology; 2015 Dec; 99():600-9. PubMed ID: 26318102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates.
    Ko MC; Husbands SM
    J Pharmacol Exp Ther; 2009 Jan; 328(1):193-200. PubMed ID: 18842704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial evaluating the safety, tolerance, pharmacokinetics and pharmacodynamics of HSK21542 injection in healthy volunteers.
    Shao R; Wang HY; Ruan ZR; Jiang B; Yang DD; Hu Y; Xu YC; Yang JT; Gao W; Zhao WY; Yan M; Lou H
    Basic Clin Pharmacol Toxicol; 2024 Dec; 135(6):743-754. PubMed ID: 39397291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753.
    Barber A; Bartoszyk GD; Bender HM; Gottschlich R; Greiner HE; Harting J; Mauler F; Minck KO; Murray RD; Simon M
    Br J Pharmacol; 1994 Dec; 113(4):1317-27. PubMed ID: 7889287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between
    Cao D; Huang P; Chiu YT; Chen C; Wang H; Li M; Zheng Y; Ehlert FJ; Zhang Y; Liu-Chen LY
    ACS Chem Neurosci; 2020 Oct; 11(19):3036-3050. PubMed ID: 32897695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Mass Balance and Metabolism of [
    Yuan JJ; Bian YC; Ma S; Chen W; Zhang FY; Zhang H; Miao LY
    Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):723-731. PubMed ID: 37833493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity.
    Vanderah TW; Schteingart CD; Trojnar J; Junien JL; Lai J; Riviere PJ
    J Pharmacol Exp Ther; 2004 Jul; 310(1):326-33. PubMed ID: 14993260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
    Schattauer SS; Kuhar JR; Song A; Chavkin C
    Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonist-Promoted Phosphorylation and Internalization of the Kappa Opioid Receptor in Mouse Brains: Lack of Connection With Conditioned Place Aversion.
    Chen C; Huang P; Bland K; Li M; Zhang Y; Liu-Chen LY
    Front Pharmacol; 2022; 13():835809. PubMed ID: 35652052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.
    Ko MC; Husbands SM
    Handb Exp Pharmacol; 2022; 271():435-452. PubMed ID: 33274403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.
    Inan S; Cowan A
    Handb Exp Pharmacol; 2022; 271():275-292. PubMed ID: 33296031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.
    Kaski SW; White AN; Gross JD; Trexler KR; Wix K; Harland AA; Prisinzano TE; Aubé J; Kinsey SG; Kenakin T; Siderovski DP; Setola V
    J Pharmacol Exp Ther; 2019 Nov; 371(2):487-499. PubMed ID: 31492823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.